- Adamis Pharmaceuticals Corporation ADMP has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose.
- "Based on FDA feedback received during our Type A meeting in April, we have resubmitted our NDA for ZIMHI, which I am confident fully addresses the issues raised in the Complete Response Letter," said President and CEO Dr. Dennis J. Carlo.
- In November last year, the company received a CRL. The FDA questions were generally related to new Chemistry, Manufacturing, and Controls issues.
- Price Action: ADMP shares are trading 4.02% higher at $0.74 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
